A Phase 2, Sequential Parallel Comparison, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Weekly and Daily Doses of NYX-783 in Subjects with Post-Traumatic Stress Disorder

    Not Recruiting
Updated on 16 August 2022


To demonstrate that NYX-783 is superior to placebo in reducing the severity of PostTraumatic Stress Disorder (PTSD) symptoms as measured by the Clinician Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (CAPS-5) total score.


Condition Post-Traumatic Stress Disorders
Clinical Study IdentifierTX218078
Last Modified on16 August 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note